Summary
Other Scenarios:
- ABT - GSK
- ABT - DNA
- GSK - PDLI
- DNA - PDLI
| Buyer: | Abbott Laboratories (ABT) | Last Price: | 50.75 | Market Cap.: | 78.74B |
|---|---|---|---|---|---|
| Target: | PDL BioPharma Inc. (PDLI) | Last Price: | 9.40 | Market Cap.: | 1.12B |
Lines of Business Summary:
- Abbott Laboratories (ABT) competes in 1 industry and 297 product/service groups
- PDL BioPharma Inc. (PDLI) competes in 1 industry and 12 product/service groups
- A combined entity will have 1% Product/Service Group overlap
- Abbott Laboratories (ABT) has 5 and PDL BioPharma Inc. (PDLI) has 0 suppliers that rely on a material % of their business. They share 0 in common.
- Abbott Laboratories (ABT) has 0 and PDL BioPharma Inc. (PDLI) has 2 customers that derive significant revenue from each. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
Healthcare |
|
|
844 |
Biopharmaceuticals |
|
|
368 |
|
Medical Devices |
|
225 | |
|
Nutritional Health |
|
28 | |
|
Outsourced Services |
|
|
48 |
|
Scientific Products |
|
23 | |
|
Veterinary Products and Services |
|
7 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 449)
|
Target (Total: 8)
|
Buyer
|
Target
|
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 57)
|
Target (Total: 2)
|
Buyer (Total: 26)
|
Target (Total: 12)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 68,000 | 887 |
| Revenue Per Employee | 442,250.5 | 348,577.5 |
| Total Revenue | 7,497.7 | 77.3 |
| Total Expenses | 6,101.1 | 64.3 |
Other Revenue
|
0.0 | 0.0 |
|
Cost of Revenue
|
3,352.9 | 0.0 |
|
SG&A Expense
|
2,067.9 | 18.5 |
|
Research & Development
|
680.4 | 44.7 |
|
Other Operating Expense
|
0.0 | 0.0 |
|
Operating Income
|
1,396.5 | 13.1 |
|
Unusual Income
|
0.0 | 1.0 |
|
LT Debt to Capital
|
30.45 | 88.93 |
|
Fwd P/E
|
15.37 | 12.78 |
|
Fwd P/Rev
|
2.67 | 3.62 |
| Book Value | 19,345.8 | 66.4 |
|
Curr Portion of LTD/Cap Lease
|
1,501.2 | 0.8 |
Individual Company Summary
Focused
Buyer
Focused ():
Healthcare > Biopharmaceuticals
Target
Focused ():
Healthcare > Biopharmaceuticals
Business Description
Buyer
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a diversified line of healthcare products. It has four segments. The Pharmaceutical Products segment?s products include adult and pediatric pharmaceuticals. The Diagnostic Products segment?s products include diagnostic systems and tests for blood banks, hospitals, commercial laboratories, physicians? offices, alternate care testing sites, plasma protein therapeutic companies and consumers. The Nutritional Products segment?s products include a line of pediatric and adult nutritional. The Vascular Products segment?s products include a line of coronary, endovascular and vessel closure devices. In February 2008, the United States Food and Drug Administration (FDA) approved the Company's SIMCOR (Niaspan/simvastatin), a medicine for cholesterol management. In January 2008, Abbott?s HUMIRA (adalimumab) received approval from FDA, for moderate to severe chronic plaque psoriasis.
Target
PDL BioPharma Inc. is a biopharmaceutical company focused on the discovery and development of novel antibodies in oncology and immunologic diseases. It receives royalties and other revenues through licensing agreements with various biotechnology and pharmaceutical companies based on its antibody humanization technology platform. These licensing agreements have contributed to the development by the Company?s licensees of nine marketed products. The Company has several investigational compounds in clinical development for severe or life-threatening diseases, two of which it is developing in collaboration with Biogen Idec MA, Inc. (Biogen Idec). Its products include Daclizumab, Volociximab, HuLuc63, PDL192 and Nuvion. In March 2008, the Company closed the sale of the Cardiovascular Assets, which included Cardene, to EKR Therapeutics, Inc (EKR). However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
56.26 | 100 |
|
Operating Margin %
|
18.99 | 23.28 |
|
Quick Ratio
|
0.92 | 8.11 |
|
Current Ratio
|
1.59 | 8.34 |
|
Coverage Ratio
|
-0.03 | 0.02 |
| Total Assets | 41,753.0 | 718.2 |
| Return on Equity % | 23.51 | 98.81 |
| Return on Assets % | 10.89 | 9.13 |
|
Cash+ ST Inv. Per Share
|
2.41 | 3.63 |
| Total Debt | 10,564.5 | 533.8 |
| Total Debt to Equity % | 54.61 | 804.19 |
| Total Debt to Tangible Equity % | 360.34 | 911.61 |
|
Debt to Asset %
|
25.30 | 74.32 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
|
Healthcare |
|
|
Biopharmaceuticals |
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
|
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
|
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
|
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
|
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Transplantation
The Transplantation Subsectors includes therapeutics that treat rejection and infection associated with tissue transplantation into the human body.
|
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
|
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
|
|
|
|
Medical Devices |
|
|
|
Cardiology
The Cardiology Subsector includes medical devices that diagnose, monitor, and treat diseases affecting the heart and proximal blood vessels. Common devices include vital sign monitors, cardiac defibrillators, pacemakers, and other surgical equipment.
|
|
|
|
Clinical Diagnostics
The Clinical Diagnostics Subsector includes medical devices that analyze human body specimens within a medical setting. These devices, including equipment, biological and chemical reagents are primarily used for the diagnosis of diseases.
|
|
|
|
Drug Delivery
The Drug Delivery Subsector includes medical devices that facilitate the delivery of medications through different anatomical entryways, including blood vessels, skin, the mouth, and the lungs. Common devices in this sector include vascular access catheters, needles, implants, and inhalers.
|
|
|
|
Gastroenterology
The Gastroenterology Subsector includes medical devices that diagnosis and treat conditions affecting the stomach and intestinal tract.
|
|
|
|
General Surgery
The General Surgery Subsector includes medical devices that perform general, non-specialty surgeries; these devices are often general in scope and are used in procedures involving various parts of the body.
|
|
|
|
Medical Supplies
The Medical Supplies Subsector includes basic and consumable products that are widely used in healthcare settings.
|
|
|
|
Orthopedics
The Orthopedics Subsector includes medical devices that diagnose and treat musculoskeletal diseases involving muscles, bones and joints.
|
|
|
|
Radiology
The Radiology Subsector includes medical devices that generate images of internal physiology.
|
|
|
|
Transfusion Medicine
The Transfusion Medicine Subsector includes medical devices and accessories that prepare or implement blood transfusion.
|
|
|
|
Urology
The Urology Subsector includes medical that diagnose and treat urinary tract and male reproductive disorders.
|
|
|
|
Vascular
The Vascular Subsector includes medical devices that diagnose and treat of conditions affecting the blood vessels.
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements
The Dietary/Naturopathic Subsector includes nutritional biochemicals and nutrients derived from natural sources that are intended to support health.
|
|
|
|
Outsourced Services |
|
|
|
Drug Delivery Technology
The Drug Delivery Technology Subsector includes companies that develop novel delivery methods for therapeutics.
|
|
|
|
Drug Discovery Services
The Drug Discovery Services Subsector includes companies that provide biopharmaceutical companies with novel biological targets and drug leads.
|
|
|
|
Scientific Products |
|
|
|
Analytical Instruments
The Analytical Instruments Subsector includes scientific products that determine the quantitative and qualitative nature of biochemical samples.
|
|
|
|
Bioanalytical
The Bioanalytical Subsector includes scientific products, devices, apparatuses, and consumables used to determine the quantitative and qualitative nature of a biological samples.
|
|
|
|
Veterinary Products and Services |
|
|
|
Veterinary Diagnostics
The Veterinary Diganostics Subsector includes companies that manufacture veterinary diagnostics for the detection and monitoring of veterinary diseases.
Buyer Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
Healthcare |
|
|
|
Biopharmaceuticals |
|
|
Cardiovascular System |
|
|
Heart Disorders |
|
|
|
Angina |
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat chest pains by preventing the entry of calcium into heart muscle cells.
Buyer Products:
|
|
|
|
Heart Failure (HF) |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat the ineffective pumping of the heart by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Myofilament Calcium Sensitizing Agents
Therapeutics that treat the ineffective pumping of the heart by increasing the sensitivity of the heart to calcium.
Buyer Products:
|
|
|
|
Myocardial Infarction (MI) |
|
|
|
Free Fatty Acid Inhibitors
Therapeutics that treat irreversible damage to the heart muscle by inhibiting the release of fatty acids from adipose tissue.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Vascular Disorders |
|
|
|
Atherosclerosis |
|
|
|
Free Fatty Acid Inhibitors
Therapeutics that treat the narrowing or hardening of arteries by inhibiting the release of fatty acids from adipose tissue.
Buyer Products:
|
|
|
|
Deep Vein Thrombosis (DVT) |
|
|
|
Thrombolytic Agents
Therapeutics that prevent or treat vascular obstruction by dissolving blood clots in blood vessels.
Buyer Products:
|
|
|
|
Hypertension |
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that treat high blood pressure by blocking alpha adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Calcium Channel Blockers
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system and preventing the entry of calcium into heart muscle cells.
Buyer Products:
|
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor.
Buyer Products:
|
|
|
|
Angiotensin II Receptor Antagonists/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Peripheral Vascular Disease |
|
|
|
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat arterial obstruction outside of the heart by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Dermatology |
|
|
|
Lesion/Scaling Disorders |
|
|
|
Psoriasis |
|
|
|
Immunosuppressants
Therapeutics that treat a slow growing, chronic inflammatory skin disorder characterized by dry, scaling patches by suppressing the immune system.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat psoriasis by binding to certain receptors on antigens associated with the disease, thus modulating the immune reaction.
Buyer Products:
|
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat psoriasis by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Gastrointestinal Tract Disorders |
|
|
|
Gastroduodenal Disorders |
|
|
|
Peptic Ulcers |
|
|
|
Duodenal |
|
|
|
Antisecretory Agents/Penicillin Derivatives/Macrolides
Therapeutics that treat peptic ulcers by inhibiting the secretion of acid as well as treating related infections with antibiotics.
Buyer Products:
|
|
|
|
Intestinal Disorders |
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Crohn`s Disease |
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat Crohn's Disease by inhibiting the action of Tumor Necrosis Factor (TNF), a key component of the inflammation process.
Buyer Products:
|
|
|
|
Ulcerative Colitis |
|
|
|
Monoclonal Antibodies
Therapeutics that treat ulcerative colitis through modulation of immune pathways implicated in the progression of the disease.
Target Products:
|
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat ulcerative colitis by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Endocrinology/Metabolism |
|
|
|
Intermediary Metabolism Disorders |
|
|
|
Hypercholesterolemia |
|
|
|
Free Fatty Acid Inhibitors
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue.
Buyer Products:
|
|
|
|
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat elevated cholesterol by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)/Plasma Triglyceride Reducing Agents (Fibrate Cmpnds)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process and reduce cholesterol levels by reducing the levels of very low-density lipoprotein (LDL) and increasing the levels of high-density lipoproteins (HDL).
Buyer Products:
|
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds)
Therapeutics that reduce cholesterol levels by reducing the levels of low-density lipoproteins (LDL) and increasing levels of high-density lipoproteins (HDL).
Buyer Products:
|
|
|
|
Hyperlipidemia |
|
|
|
Free Fatty Acid Inhibitors
Therapeutics that inhibit the release of fatty acids from adipose tissue.
Buyer Products:
|
|
|
|
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hyperlipidemia by inhibiting the release of free fatty acid from adipose tissues as well as blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)/Plasma Triglyceride Reducing Agents (Fibrate Cmpnds)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process and reduce the levels of very low-density lipoprotein and increase levels of high-density lipoproteins.
Buyer Products:
|
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds)
Therapeutics that reduce the levels of very low-density lipoprotein and increase levels of high-density lipoproteins.
Buyer Products:
|
|
|
|
Parathyroid Gland Disorders |
|
|
|
Hyperparathyroidism (HPT) |
|
|
|
Vitamin D Analogs
Therapeutics that act similar to Vitamin D.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Pituitary Gland Disorders |
|
|
|
Pituitary Hyperthyroidism (TSH-Induced) |
|
|
|
Thyroid Hormones
Hormones that affect the rate of cell metabolism and blood calcium levels.
Buyer Products:
|
|
|
|
Reproductive Disorders |
|
|
|
Abnormal Puberty |
|
|
|
Precocious |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat abnormal puberty by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Thyroid Gland Disorders |
|
|
|
Hypothyroidism |
|
|
|
Thyroid Hormones
Therapeutics that treat a deficiency in thyroid activity by supplementing thyroid hormones.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Serum Factor Disorders |
|
|
|
Hypercholesterolemia |
|
|
|
Free Fatty Acid Inhibitors
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue.
Buyer Products:
|
|
|
|
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)/Plasma Triglyceride Reducing Agents (Fibrate Cmpnds)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process and reduce the levels of very low-density lipoprotein and increase levels of high-density lipoproteins.
Buyer Products:
|
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds) |
|
|
|
Hyperlipidemia |
|
|
|
Free Fatty Acid Inhibitors
Therapeutics that inhibit the release of fatty acids from adipose tissue.
Buyer Products:
|
|
|
|
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hyperlipidemia by inhibiting the release of free fatty acid from adipose tissues as well as blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)/Plasma Triglyceride Reducing Agents (Fibrate Cmpnds)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process and reduce the levels of very low-density lipoprotein and increase levels of high-density lipoproteins.
Buyer Products:
|
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds)
Therapeutics that reduce the levels of very low-density lipoprotein and increase levels of high-density lipoproteins.
Buyer Products:
|
|
|
|
Hypokalemia |
|
|
|
Potassium Supplements
Therapeutics that treat hypokalemia by providing potassium to the body.
Buyer Products:
|
|
|
|
Immunology |
|
|
|
Autoimmune Disorders |
|
|
|
Arthritis |
|
|
|
Psoriatic Arthritis |
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat chronic inflammation of the joints coupled with red, scaly skin patches by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Immunotherapy |
|
|
|
Immunosuppressants
Therapeutics that treat chronic inflammation of the joints by inhibiting a full immune response.
Buyer Products:
|
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat chronic inflammation of the joints by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Crohn`s Disease |
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat inflammation of the gastrointestinal tract by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Ulcerative Colitis |
|
|
|
Monoclonal Antibodies
Therapeutics that treat ulcerative colitis through modulation of immune pathways implicated in the progression of the disease.
Target Products:
|
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat ulcerative colitis by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Psoriasis |
|
|
|
Immunosuppressants
Therapeutics that treat a chronic autoimmune disease characterized by thickened skin with silver scales by inhibiting a full immune response.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat psoriasis by binding to certain receptors on antigens associated with the disease, thus modulating the immune reaction.
Buyer Products:
|
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat psoriasis by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Immune Deficiency Disorders |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.
Target Products:
|
|
|
|
Infectious Diseases |
|
|
|
Bacterial |
|
|
|
Antibacterial Agents |
|
|
|
Broad Spectrum |
|
|
|
Antibiotics |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Ketolides
Therapeutics that treat a wide variety of infections by inhibiting RNA-dependent bacterial protein synthesis.
Buyer Products:
|
|
|
|
Macrolides
Therapeutics that treat a wide variety of infections by inhibiting RNA-dependent bacterial protein synthesis.
Buyer Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
|
Otitis Media |
|
|
|
Macrolides/Sulfonamides
Therapeutics that treat infection and inflammation of the middle ear space and ear drum by inhibiting RNA-dependent bacterial protein synthesis and by inhibiting folic acid synthesis.
Buyer Products:
|
|
|
|
Viral |
|
|
|
RNA Viruses |
|
|
|
Paramyxovirus |
|
|
|
Respiratory Syncytial Virus (RSV) |
|
|
|
Monoclonal Antibodies
Therapeutics that treat viral infections in the respiratory tracts of infants with a neutralizing protein that targets a specific site on the virus.
Buyer Products:
|
|
|
|
Retrovirus |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Skeletal Disorders |
|
|
|
Joint Disorders |
|
|
|
Ankylosing Spondylitis |
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat ankylosing spondylitis by blocking the effect of TNF-alpha, a pro-inflammatory molecule.
Buyer Products:
|
|
|
|
Psoriatic Arthritis |
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat chronic inflammation of the joints by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Immunotherapy |
|
|
|
Immunosuppressants
Therapeutics that treat rheumatoid arthritis by suppressing the immune system.
Buyer Products:
|
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat chronic inflammation of the joints by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Neurological Disorders |
|
|
|
Epilepsy |
|
|
|
Partial Seizures |
|
|
|
Complex |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, which prevent nerve activation.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, that prevents nerve activation.
Buyer Products:
|
|
|
|
Simple |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat simple partial seizures by preventing the uptake of gamma-aminobutyric acid which prevents nerve activation.
Buyer Products:
|
|
|
|
Primary Generalized Seizures |
|
|
|
Absence (Petit Mal) |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Buyer Products:
|
|
|
|
Headaches |
|
|
|
Vascular (Migraine) |
|
|
|
Prophylactic Treatments |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that provide preventative treatments for migraine headaches by inhibiting the uptake of molecules that prevent nerve activation.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Psychiatric Disorders |
|
|
|
Mood Disorders |
|
|
|
Bipolar Disorders (Manic Depressive Disorders) |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat bipolar disorders by preventing the uptake of gamma-aminobutyric acid, that prevents nerve activation.
Buyer Products:
|
|
|
|
Obstetrics/Gynecology |
|
|
|
Female Genital Disorders |
|
|
|
Endometriosis |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat endometriosis by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Buyer Products:
|
|
|
|
Ovarian |
|
|
|
Abnormal Puberty |
|
|
|
Precocious |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat abnormal puberty by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of female reproductive disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of female reproductive disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Oncology |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.
Target Products:
|
|
|
|
Urology |
|
|
|
Prostate Cancer |
|
|
|
Localized |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat and manage prostate cancer by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Endothelin Receptor Antagonists
Therapeutics that treat prostate cancer by blocking the action of the endothelin protein. This inhibits the progress and subsequent metastases of prostate cancer.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat and manage prostate cancer by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations but are not curative.
Buyer Products:
|
|
|
|
Uterine Cancer |
|
|
|
Uterine Fibroids (Leiomyoma, Uterus) |
|
|
|
Progestins Receptor Modulators
Therapeutics that treat and manage non-cancerous tumors of the uterus by modulating the effects of progesterone.
Buyer Products:
|
|
|
|
Pain Management |
|
|
|
Anesthesia |
|
|
|
General (Systemic) |
|
|
|
Adjunctive |
|
|
|
Acetylcholine Blocking Agents
Therapeutics that inhibit neuromuscular activity by competing with acetylcholine at the cholinergic receptors resulting in neuromuscular blockage.
Buyer Products:
|
|
|
|
Ether-Based Agents
Therapeutics that result in anesthesia due to interfering with the physiological functioning of nerve cell membranes in the brain.
Buyer Products:
|
|
|
|
Primary |
|
|
|
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters the both the perception of pain as well as the emotional response to pain.
Buyer Products:
|
|
|
|
Narcotics |
|
|
|
Analgesics/Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters the both the perception of pain as well as the emotional response to pain.
Buyer Products:
|
|
|
|
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
|
Asthma |
|
|
|
Prophylactic Treatments |
|
|
|
Beta Adrenergic Receptor Agonists/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat asthma by reducing inflammation in the lungs with steroids and that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat asthma by reducing inflammation in the lung passages with steroids.
Buyer Products:
|
|
|
|
Respiratory Distress Syndrome (RDS) |
|
|
|
Surfactants
Therapeutics that treat RDS by modifying alveolar surface tension and thereby stabilizing the alveoli.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Transplantation |
|
|
|
Heart |
|
|
|
Rejection Prophylaxis |
|
|
|
Immunosuppressants
Therapeutics that help manage and suppress the response of the immune system to foreign tissue.
Buyer Products:
|
|
|
|
Hepatic (Liver) |
|
|
|
Rejection Prophylaxis |
|
|
|
Immunosuppressants
Therapeutics that manage and suppress the response of the immune system to foreign tissue.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the management of rejection and infection in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Renal (Kidney) |
|
|
|
Rejection Prophylaxis |
|
|
|
Immunosuppressants
Therapeutics that manage and suppress the response of the immune system to foreign tissue.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Protein-based therapeutics that target specific substances like proteins.
Target Products:
|
|
|
|
Urology |
|
|
|
Male Genital Disorders |
|
|
|
Prostate |
|
|
|
Benign Prostate Hyperplasia (BPH) |
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that increase blood flow by acting on the alpha adrenergic receptors thus causing the smooth muscle in the prostate to relax and decreasing the constriction on the urinary tract.
Buyer Products:
|
|
|
|
Testicular |
|
|
|
Abnormal Puberty |
|
|
|
Precocious |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat puberty disorders by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Buyer Products:
|
|
|
|
Urological Disorders |
|
|
|
Kidney (Renal) |
|
|
|
Chronic Renal Failure (CRF) |
|
|
|
Complications |
|
|
|
Hyperparathyroidism |
|
|
|
Vitamin D Analogs
Therapeutics that provide the body with vitamin D like substances that help regulate the levels of calcium and phosphate in the blood.
Buyer Products:
|
|
|
|
Hypocalcemia |
|
|
|
Vitamin D Analogs
Therapeutics that provide the body with vitamin D like substances that help regulate the levels of calcium and phosphate in the blood.
Buyer Products:
|
|
|
|
Weight Management |
|
|
|
Obesity |
|
|
|
Serotonin Reuptake Inhibitor
Therapeutics that suppress appetite by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Medical Devices |
|
|
|
Cardiology |
|
|
|
Diagnostic |
|
|
|
Imaging |
|
|
|
X-Ray |
|
|
|
Angiography |
|
|
|
Accessories
Various instruments used to assist in angiography procedures, including transducers, catheters, control syringes, waste systems, contrast management systems, fluid administration sets, and other related items.
Buyer Products:
|
|
|
|
Surgical |
|
|
|
General Procedure |
|
|
|
Accessories |
|
|
|
Guidewires
A small wire-like device that is threaded through a catheter to the site of interest for delivery of another apparatus like a stent.
Buyer Products:
|
|
|
|
Vessel Closure
Devices used to close heart blood vessels.
Buyer Products:
|
|
|
|
Instruments |
|
|
|
Electrical |
|
|
|
Irrigation Blowers/Misters
Instruments used to add moisture or aid onto cardiac tissue during surgery.
Buyer Products:
|
|
|
|
Procedure/Region Specific |
|
|
|
Cardiopulmonary Support |
|
|
|
Minimally Invasive |
|
|
|
Endovascular Bypass Systems
Minimally invasive device that provides cardiopulmonary support by bypassing the heart.
Buyer Products:
|
|
|
|
Coronary Artery Bypass Graft (CABG) |
|
|
|
Invasive (Open Heart) |
|
|
|
Accessories
Various instruments used to assist in open heart bypass surgery, such as sutures, needles and vessel occluders.
Buyer Products:
|
|
|
|
Manual Instruments
Various devices used to perform open heart bypass surgery that do not require electrical power, such as heart positioners, stablizers and retractors.
Buyer Products:
|
|
|
|
Shunts
Devices used to divert blood flow in order to perform surgical procedure.
Buyer Products:
|
|
|
|
Minimally Invasive |
|
|
|
Manual Instruments
Manual surgical instruments used to perform minimally invasive coronary bypass surgery, such as retractors, forceps, clamps, clip applicators, stablilizers, bisectors and other similar items.
Buyer Products:
|
|
|
|
Revascularization |
|
|
|
Atherectomy |
|
|
|
Directional Catheters
Catheter that is able to be manually directed one way or the other.
Buyer Products:
|
|
|
|
Percutaneous Transluminal Coronary Angioplasty (PTCA) |
|
|
|
Catheters |
|
|
|
Balloon |
|
|
|
Over-The-Wire
A balloon catheter that is put into position by passing it over the guidewire all the way to the coronary blockage site of interest.
Buyer Products:
|
|
|
|
Rapid Exchange
An angioplasty balloon catheter that provides flexibility, trackability, tactile feedback, and ease of use.
Buyer Products:
|
|
|
|
Guiding
Catheter used to guide the balloon into place in the coronary artery.
Buyer Products:
|
|
|
|
Restenosis Prevention |
|
|
|
Stents Systems |
|
|
|
Coated (Drug-Eluting Stents)
Stent systems coated with pharmaceuticals that aid the stent in preventing restenosis.
Buyer Products:
|
|
|
|
General
Stent systems that are not coated with additional pharmaceuticals indicated to prevent restenosis.
Buyer Products:
|
|
|
|
Valvoplasty |
|
|
|
Valves |
|
|
|
Aortic Valved Conduits |
|
|
|
Mechanical
A channel through the aorta where the blood can flow through that has a valve to stop or control the flow.
Buyer Products:
|
|
|
|
Clinical Diagnostics |
|
|
|
Chemistry |
|
|
|
Analyzers |
|
|
|
Discrete |
|
|
|
Multiple Assay
Multi-System analyzers designed for high throughput generally used in high volume clinical laboratories.
Buyer Products:
|
|
|
|
Home Testing |
|
|
|
Glucose |
|
|
|
Invasive
Devices that generally use blood samples for testing and require a needlestick or pin-prick.
Buyer Products:
|
|
|
|
Test Strips
Specific glucose test devices used with glucose monitors.
Buyer Products:
|
|
|
|
Urine |
|
|
|
Pregnancy
Home pregnancy testing kits.
Buyer Products:
|
|
|
|
Point of Care Testing |
|
|
|
Critical Care Analysis |
|
|
|
Analyzers
Chemistry analyzers which may be used for the chemical analysis of body fluids and designed for use at the bedside during the course of patient care.
Buyer Products:
|
|
|
|
Test Cartridges
Specific analyte test devices used in conjunction with critical care chemistry analyzers.
Buyer Products:
|
|
|
|
Glucose Monitoring |
|
|
|
Invasive |
|
|
|
Random Analysis
Glucose test devices which measure patient glucose levels as a blood sample is obtained.
Buyer Products:
|
|
|
|
Non-Invasive |
|
|
|
Continuous Analysis
Glucose test devices which measure patient glucose levels on a continual basis without the need to obtain patient blood..
Buyer Products:
|
|
|
|
Software
Software designed to assist in the management of patient glucose monitoring.
Buyer Products:
|
|
|
|
Reagents |
|
|
|
Calibrators |
|
|
|
Routine Analyte |
|
|
|
Multiple
Calibrators which contain multiple specific analytes used to establish the accuracy of chemistry analyzers.
Buyer Products:
|
|
|
|
Test Kits |
|
|
|
Hemoglobin |
|
|
|
Glycohemoglobin
Test kits used to measure glycohemoglobin in human blood.
Buyer Products:
|
|
|
|
Photometric |
|
|
|
Cardiac |
|
|
|
HDL Cholesterol
High density lipoprotein cholesterol.
Buyer Products:
|
|
|
|
LDL Cholesterol
Low density lipoprotein cholesterol.
Buyer Products:
|
|
|
|
Enzymes
Photometric test kits which quantitatively measure for specific metabolic enzymes in body fluids.
Buyer Products:
|
|
|
|
Routine Metabolic Analytes
Photometric test kits which quantitatively measure for specific metabolic analyses in body fluids.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Analyzers |
|
|
|
Accessories
Disposables,consumables or peripheral equipment designed to augment or to be used in conjunction with hematology analyzers.
Buyer Products:
|
|
|
|
Multiple Parameter
Hematology analyzers designed for use in determining multiple hematological parameters in a clinical setting.
Buyer Products:
|
|
|
|
Reagents |
|
|
|
Analyzer Reagents
Reagents which are used with automated hematology analyzers.
Buyer Products:
|
|
|
|
Stain Kits
Vital stains specifically designed to stain blood cells in order to differentiate and identify specific types of blood cells.
Buyer Products:
|
|
|
|
Hemostasis/Coagulation |
|
|
|
Analyzers |
|
|
|
Point Of Care Testing
Devices used to perform coagulation studies at the point of patient care. For example, at the bedside or doctor's office.
Buyer Products:
|
|
|
|
Reagents |
|
|
|
Test Kits |
|
|
|
D-Dimer
Test kits used to assay for D-Dimer, a component of fibrin (clot) degradation..
Buyer Products:
|
|
|
|
Fibrin Degradation Products
Test kits used to assay for fibrin, (clot), degradation products.
Buyer Products:
|
|
|
|
Prothrombin Time
Reagents used to perform prothrombin time assays.
Buyer Products:
|
|
|
|
Specialty Assays
Test kits used to assay for special, esoteric coagulation factors..
Buyer Products:
|
|
|
|
Histology |
|
|
|
Processing Equipment |
|
|
|
Denaturator
Equipment which is used to denature proteins as part of histological tissue processing.
Buyer Products:
|
|
|
|
Slide Makers
Automatic slide makers.
Buyer Products:
|
|
|
|
Tissue Processors
Instrument used for the automated processing tissue samples.
Buyer Products:
|
|
|
|
Reagents |
|
|
|
Control Slides
Microscopic slides with known staining characteristics.
Buyer Products:
|
|
|
|
Kits |
|
|
|
DNA Probes
Staining kits which utilize DNA probes to mark specific cells for staining.
Buyer Products:
|
|
|
|
In-Situ Hybridization (ISH)
Staining kits which utilize In-Situ hybridization techniques to mark specific cells for staining.
Buyer Products:
|
|
|
|
Immunoassays |
|
|
|
Analyzers |
|
|
|
Infectious Disease
Immunoassay analyzers designed to test for agents of infectious disease.
Buyer Products:
|
|
|
|
Multiple Assay
Immunoassay analyzer designed to perform multiple assays over multiple modalities.
Buyer Products:
|
|
|
|
Toxicology/Abuse Drugs
Immunoassay analyzers designed to perform toxicology studies in a clinical setting.
Buyer Products:
|
|
|
|
Reagents |
|
|
|
Calibrators |
|
|
|
Immunoassay
Reagents with known values (standards) designed to adjust parameters on immunoassay instrumentation so as to maximize accuracy of the analysis.
Buyer Products:
|
|
|
|
Therapeutic Drugs
Calibrators used in the measurement of therapeutic drugs.
Buyer Products:
|
|
|
|
Toxicology/Abuse Drugs
Calibrators used in the measurement of drugs of abuse.
Buyer Products:
|
|
|
|
Controls |
|
|
|
Immunoassay
Controls used to verify the accuracy of immuassay test systems.
Buyer Products:
|
|
|
|
Therapeutic Drugs
Controls which contain known concentrations of specific therapeutic drugs used to verify the performance of therapeutic drug testing systems.
Buyer Products:
|
|
|
|
Toxicology/Abuse Drugs
Controls which contain known concentrations of specific drugs used to verify the performance of drug testing systems.
Buyer Products:
|
|
|
|
Test Kits |
|
|
|
Allergy |
|
|
|
Total IgE
Immunoassay test kits which quantitatively measures total IgE antibody in plasma or serum.
Buyer Products:
|
|
|
|
Autoimmune |
|
|
|
Anti-Thyroglobulin Antibody
Immunoassay test kits which quantitatively measures anti-thyroglobulin antibody in plasma or serum.
Buyer Products:
|
|
|
|
Anti-Thyroid Microsomal
Immunoassay test kits which quantitatively measures anti thyroid mycrosomal antibodies in plasma or serum.
Buyer Products:
|
|
|
|
Anti-Thyroid Peroxidase
Immunoassay test kits which quantitatively measures anti-thyroid antibodies in plasma or serum.
Buyer Products:
|
|
|
|
Bacterial |
|
|
|
Cerebral Spinal Fluid
Immunoassay kits which test for the presence of infectious disease or previous infection in cerebral spinal fluid.
Buyer Products:
|
|
|
|
Chlamydia
Immunoassay kits which test for current or previous infection caused by the Chlamydia organism.
Buyer Products:
|
|
|
|
E coli 0157
Immunoassay kits which test for current or previous infection caused by the E.coli 0157 bacteria.
Buyer Products:
|
|
|
|
Streptococcus Group A
Immunoassay kits which test for current infection caused by the Streptococcus A bacteria.
Buyer Products:
|
|
|
|
Streptococcus Group B
Immunoassay kit which tests for current infection caused by the Streptococcus B bacteria.
Buyer Products:
|
|
|
|
Syphilis
Immunoassay kits which test for current or previous infection caused by the Syphilis bacteria.
Buyer Products:
|
|
|
|
Mycological (Fungal) |
|
|
|
Cryptococcus
Immunoassay kit which tests for the presence cryptococcus antigen.
Buyer Products:
|
|
|
|
Parasitic |
|
|
|
Toxoplasma
Immunoassay kit which tests for current or previous infection caused by Toxoplasma.
Buyer Products:
|
|
|
|
Special/Immuno Chemistry |
|
|
|
Anemia |
|
|
|
Ferritin
Immunoassay test kit which quantitatively measures ferritin in plasma or serum.
Buyer Products:
|
|
|
|
Folate
Immunoassay test kit which quantitatively measures folate in plasma or serum.
Buyer Products:
|
|
|
|
Transferrin
Immunoassay test kit which quantitatively measures transferrin in plasma or serum.
Buyer Products:
|
|
|
|
Vitamin B12
Immunoassay test kit which quantitatively measures ferritin in plasma or serum.
Buyer Products:
|
|
|
|
Cancer Marker |
|
|
|
CA 125
Immunoassay test kits which quantitatively measures for CA 125, a tumor marker in plasma or serum.
Buyer Products:
|
|
|
|
CA 15-3
Immunoassay test kits which quantitatively measures for CA 15-3, a tumor marker, in plasma or serum.
Buyer Products:
|
|
|
|
CA 19-9
Immunoassay test kits which quantitatively measures for CA 19-9, a tumor markers in plasma or serum.
Buyer Products:
|
|
|
|
CEA
Immunoassay test kits which quantitatively measures for CEA, carcinoembryonic antigen, in plasma or serum.
Buyer Products:
|
|
|
|
PSA/Prostate Specific Protein
Immunoassay test kits which quantitatively measures for prostate specific antigen or prostate specific protein in plasma or serum.
Buyer Products:
|
|
|
|
Cardiac |
|
|
|
Myocardial Infarction/Heart Failure |
|
|
|
B-Type Natriuretic Peptide (BNP)
Immunoassay test kits which quantitatively measure B-type natriuretic peptide in plasma or serum.
Buyer Products:
|
|
|
|
CK-MB
Immunoassay test kits which quantitatively measure creatinine kinase-MB fraction in plasma or serum.
Buyer Products:
|
|
|
|
Homocysteine
Immunoassay test kits which quantitatively measure for homocysteine in plasma or serum.
Buyer Products:
|
|
|
|
Myoglobin
Immunoassay test kits which quantitatively measure for myoglobin in plasma or serum.
Buyer Products:
|
|
|
|
Troponin
Immunoassay test kits which quantitatively measure for troponin in plasma or serum.
Buyer Products:
|
|
|
|
Endocrine |
|
|
|
Insulin
Immunoassay test kits which quantitatively measures iinsulin in plasma or serum.
Buyer Products:
|
|
|
|
Fertility/Reproduction |
|
|
|
Alpha Fetoprotein (AFP)
Test kits to measure maternal AFB in order to screen for fetal neural tube defects. May have other fetal screening tests included.
Buyer Products:
|
|
|
|
B-hCG
Immunoassay test kits which quantitatively measures beta hCG, human chorionic gonadotrophin, in plasma or serum.
Buyer Products:
|
|
|
|
Estradiol
Immunoassay test kits which quantitatively measures estradiol in plasma or serum.
Buyer Products:
|
|
|
|
Estriol
Immunoassay test kits which quantitatively measures estriol in plasma or serum.
Buyer Products:
|
|
|
|
FSH
Immunoassay test kits which quantitatively measures FSH, follicle stimulating hormone, in plasma or serum.
Buyer Products:
|
|
|
|
Fetal Development |
|
|
|
Fetal Lung
Immunoassay test kits which measure for fetal lung maturity in amniotic fluid.
Buyer Products:
|
|
|
|
Lutenizing Hormone
Immunoassay test kits which quantitatively measures LH, lutinizing hormone, in plasma or serum.
Buyer Products:
|
|
|
|
Pregnancy Tests |
|
|
|
Serum/Urine
Immunoassay test kits which determine pregnancy in serum or urine.
Buyer Products:
|
|
|
|
Urine
Immunoassay test kits which determine pregnancy from urine.
Buyer Products:
|
|
|
|
Progesterone
Immunoassay test kits which quantitatively measures progesterone in plasma or serum.
Buyer Products:
|
|
|
|
Prolactin
Immunoassay test kits which quantitatively measures prolactin in plasma or serum.
Buyer Products:
|
|
|
|
SHBG
Immunoassay test kits which quantitatively measures SHBG in plasma or serum.
Buyer Products:
|
|
|
|
Testosterone
Immunoassay test kits which quantitatively measures testosterone in plasma or serum.
Buyer Products:
|
|
|
|
Therapeutic Drugs
Immunoassay test kits which quantitatively measure for therapeutic drugs in serum or urine using automated instrumentation..
Buyer Products:
|
|
|
|
Thyroid |
|
|
|
Free T4
Immunoassay test kits which quantitatively measure for free thyoxine hormone in plasma or serum.
Buyer Products:
|
|
|
|
T3 Uptake
Test kits which determine the serums' ability to bind thyroid hormone (T3), a parameter directly linked to the ability to maintain normal thyroid hormone levels.
Buyer Products:
|
|
|
|
Thyroid Stimulating Hormone (TSH)
Kits or reagents designed to detect and quantitate the concentration of Thyroid Stimulating Hormone in human blood samples.
Buyer Products:
|
|
|
|
Total T4
Immunoassay test kits which quantitatively measure for total thyroxine in plasma or serum.
Buyer Products:
|
|
|
|
Toxicology/Abuse Drugs |
|
|
|
Single Drug Kit
Immunoassay test kits which measure for a specific drug of abuse in body fluids.
Buyer Products:
|
|
|
|
Transplant |
|
|
|
Cyclosporin
Immunoassay test kits which quantitatively measure for cyclosporin levels in plasma or serum.
Buyer Products:
|
|
|
|
Tacrolimus
Immunoassay test kits which quantitatively measure for tacrolimus levels in plasma or serum.
Buyer Products:
|
|
|
|
Viral |
|
|
|
Cytomegalovirus
Immunoassay kit which tests for the presence of infectious disease or previous infection caused by cytomegalovruses.
Buyer Products:
|
|
|
|
HTLV I/II/III
Immunoassay kit which tests for the presence of infectious disease or previous infection caused by the HTLV I, II and III viruses.
Buyer Products:
|
|
|
|
Hepatitis
Immunoassay kits which tests for current or previous infection caused by Hepatitis viruses.
Buyer Products:
|
|
|
|
Herpes Simplex
Immunoassay kit which tests for the presence of infectious disease or previous infection caused by the Herpes simplex viruses.
Buyer Products:
|
|
|
|
Human Immunodeficiency Virus (HIV) |
|
|
|
Serum |
|
|
|
EIA
Immunoassay kit which tests for the presence of infectious disease caused by the Human Immunodeficiency Virus in serum or plasma using EIA methodologies.
Buyer Products:
|
|
|
|
Genotyping
Tests that "fingerprint" HIV according to chromosomal makeup in order to track specific strains.
Buyer Products:
|
|
|
|
Rapid
Immunoassay kit which tests for the presence of infectious disease caused by the Human Immunodeficiency Virus in serum or plasma using rapid EIA methodologies.
Buyer Products:
|
|
|
|
Influenza
Immunoassay kit which tests for the presence of infectious disease caused by Influenza viruses.
Buyer Products:
|
|
|
|
RSV
Immunoassay kit which tests for the presence of infectious disease caused by RSV.
Buyer Products:
|
|
|
|
Rotavirus
Immunoassay kit which tests for the presence of infectious disease caused by Rotavirus.
Buyer Products:
|
|
|
|
Rubella
Immunoassay kit which tests for the presence of infectious disease caused by the mumps virus.
Buyer Products:
|
|
|
|
Microbiology |
|
|
|
Culture and Sensitivity |
|
|
|
Identification/Manual |
|
|
|
Reagents |
|
|
|
Identification Confirmation |
|
|
|
Bacterial |
|
|
|
Bordetella
Test kits used to identify Bordetella bacteria in a culture source.
Buyer Products:
|
|
|
|
Brucella
Test kits used to identify Brucella bacteria in a culture source.
Buyer Products:
|
|
|
|
E. coli
Test kits used to identify E coli bacteria in a culture source using agglutinating sera.
Buyer Products:
|
|
|
|
Haemophilus influenzae
Test kits used to identify Haemophilus influenzae bacteria in a culture source.
Buyer Products:
|
|
|
|
Neisseria
Test kits used to identify Niesseria bacteria in a culture source.
Buyer Products:
|
|
|
|
Salmonella Grouping
Test kits used to identify Salmonella bacteria in a culture source.
Buyer Products:
|
|
|
|
Shigella Grouping
Test kits used to identify Shigella bacteria in a culture source.
Buyer Products:
|
|
|
|
Staphylococcus/MRSA
Test kits used to identify Staphylococcus bacteria in a culture source.
Buyer Products:
|
|
|
|
Streptococcus
Test kits used to identify Streptococcus bacteria in a culture source.
Buyer Products:
|
|
|
|
Vibrio cholerae
Test kits used to identify Vibrio cholerae bacteria in a culture source.
Buyer Products:
|
|
|
|
Mycological (Fungal) |
|
|
|
Candida
Confirmatory test for identification of suspected C. albicans in culture.
Buyer Products:
|
|
|
|
Genetic Probes/PCR |
|
|
|
Automated Analyzers
Analyzers designed for genetic probe assays.
Buyer Products:
|
|
|
|
Reagents |
|
|
|
Bacterial |
|
|
|
Chlamydia
Genetic probes for detection of Chlamydia organisms.
Buyer Products:
|
|
|
|
Gonorrhea
Genetic probes for the detection of gonorrhea.
Buyer Products:
|
|
|
|
Viral |
|
|
|
Cytomegalovirus
Genetic probe for detection and/or quantitation of Cytomegalovirus.
Buyer Products:
|
|
|
|
Hepatitis B Virus
Genetic probes for detection and/or quantitation of HBV.
Buyer Products:
|
|
|
|
Human Immunodeficiency Virus (HIV)
Genetic probes for detection and quantification of HIV.
Buyer Products:
|
|
|
|
Human Papilloma Virus
Genetic probes for the detection of HPV.
Buyer Products:
|
|
|
|
Specimen Collection |
|
|
|
Microbiological |
|
|
|
Viral Transport Media
Transport media which is enhanced to maintain the viability of viruses or similar organisms for culture.
Buyer Products:
|
|
|
|
Drug Delivery |
|
|
|
Infusion Therapy |
|
|
|
Accessories |
|
|
|
Pump Sets
Pump sets designed specifically for infusion therapy.
Buyer Products:
|
|
|
|
Vascular Access Flushing
Medical devices used for flushing the area where vascular access was gained for infection prevention.
Buyer Products:
|
|
|
|
Delivery Systems |
|
|
|
Pumps |
|
|
|
Single Channel
Single channel pump designed to deliver only one infusion therapy to patients.
Buyer Products:
|
|
|
|
Syringe
Syringe used in place of a pump to deliver infusion therapy.
Buyer Products:
|
|
|
|
Vascular Access |
|
|
|
Extended In Dwelling Catheters |
|
|
|
Central Venous Catheters (CVC)
Catheters designed to handle high volume flow.
Buyer Products:
|
|
|
|
Peripheral Intravenous Catheters |
|
|
|
Infusion Sets
Complete infusion sets containing peripheral intravenous catheters.
Buyer Products:
|
|
|
|
Percutaneous (Subcutaneous/Intramuscular/Intravenous) |
|
|
|
Automatic Injectors
Pen-shaped medical devices used to contain and deliver liquid medications to a specified needle depth with a press of a button.
Buyer Products:
|
|
|
|
Syringes |
|
|
|
General Purpose |
|
|
|
Permanent Needle
General glass or plastic syringes with a built-in fixed needle.
Buyer Products:
|
|
|
|
Specialty |
|
|
|
Insulin
Syringes designed for the delivery of insulin for diabetic patients
Buyer Products:
|
|
|
|
Prefillable
Syringes designed for the advanced loading and storage of medications prior to use
Buyer Products:
|
|
|
|
Pulmonary Delivery |
|
|
|
Aerosol Therapy |
|
|
|
Metered Dose |
|
|
|
Liquid |
|
|
|
Breath Actuated (BAI)
Inhalation devices which are activated by the patients' inspiration
Buyer Products:
|
|
|
|
Transdermal |
|
|
|
Iontophoresis/Electrotransport |
|
|
|
Patch-Integrated
Transdermal delivery systems which utilize a epidermal patch for iontophoretic drug delivery
Buyer Products:
|
|
|
|
Patches
Medical patches applied to the skin which mediate sustained release of medications through the skin
Buyer Products:
|
|
|
|
Gastroenterology |
|
|
|
Surgical |
|
|
|
General Procedure |
|
|
|
Minimally Invasive/Oral Percutaneous Rectal |
|
|
|
Region Specific |
|
|
|
Small Intestine |
|
|
|
Jejunostomy |
|
|
|
Feeding/Decompression Tubes
A device that is inserted into the jejunum to assist the delivery of food or relief of tension or pressure.
Buyer Products:
|
|
|
|
Stomach |
|
|
|
Gastrostomy |
|
|
|
Feeding Apparatus
Devices that are inserted into the stomach to facilitate feeding, such as feeding tubes and buttons.
Buyer Products:
|
|
|
|
Treatment |
|
|
|
Stomach |
|
|
|
Enteral Feeding |
|
|
|
Pumps
Mechanical devices that push liquid food into the stomach, including both ambulatory and stationary pumps.
Buyer Products:
|
|
|
|
Sets
Complete instrument systems that perform enteral feeding procedures.
Buyer Products:
|
|
|
|
Tubes |
|
|
|
Feeding
A tube that carries food to the stomach.
Buyer Products:
|
|
|
|
General Surgery |
|
|
|
Invasive |
|
|
|
Accessories |
|
|
|
Guidewires
Guidewires used to lead other medical devices into place during surgical procedures
Buyer Products:
|
|
|
|
Autotransfusion |
|
|
|
Systems
Complete medical systems used for the collection, storage, and infusion of blood during autotransfusions
Buyer Products:
|
|
|
|
Surgical-Site Treatments |
|
|
|
Closure |
|
|
|
Sutures/Loops
Thread-like material used for stitching up an interventional area for surgical procedures, including both absorbable and non-absorbable materials. Sutures that biodegrade and are absorbed in the body after surgical procedures.
Buyer Products:
|
|
|
|
Sealants |
|
|
|
Adhesives
Glue based products used to seal tissue during surgical procedures
Buyer Products:
|
|
|
|
Medical Supplies |
|
|
|
Safety and Sterilization |
|
|
|
Safety |
|
|
|
Waste Management
Products used to control and contain biohazardous materials, such as chemical waste, fluid waste, and solid waste. These products may include bags, containers, and other more advanced waste treatment systems.
Buyer Products:
|
|
|
|
Orthopedics |
|
|
|
Surgical |
|
|
|
Procedure Specific |
|
|
|
Bone Loss Reconstruction |
|
|
|
General |
|
|
|
Bone Fillers
Devices used to fill the formed bone cavity with hardening material.
Buyer Products:
|
|
|
|
Treatment |
|
|
|
Braces/Supports |
|
|
|
Passive/Orthosis
Apparatus used to support, align, prevent, or correct deformities or to improve the function of movable parts of the body, such as the ankle, elbow, foot, hip, knee, spine, writs and other body parts.
Buyer Products:
|
|
|
|
Radiology |
|
|
|
Nuclear |
|
|
|
Gamma Camera |
|
|
|
Contrast Agents |
|
|
|
Radionuclides |
|
|
|
Adjuncts
Radioactive materials that are introduced to the body for nuclear imaging purposes.
Buyer Products:
|
|
|
|
Transfusion Medicine |
|
|
|
Immunohematology |
|
|
|
Non-Automated Typing |
|
|
|
Reagents |
|
|
|
Antibody Identification
Reagents used to identify specific antibodies in blood banking procedures.
Buyer Products:
|
|
|
|
Antibody Screening |
|
|
|
Infectious Disease
Test kits used in blood banks to test for infectious diseases.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Surgical |
|
|
|
General Procedure |
|
|
|
Minimally Invasive/Cystoscopy |
|
|
|
Irrigation Pumps/Systems
Surgical instruments that pump fluids to irrigate/moisten the surface of the urinary organs
Buyer Products:
|
|
|
|
Vascular |
|
|
|
Diagnostic |
|
|
|
Imaging |
|
|
|
X-Ray |
|
|
|
Angiography |
|
|
|
Accessories
Various instruments used to assist in angiography procedures, including transducers, catheters, control syringes, waste systems, contrast management systems, fluid administration sets, and other related items.
Buyer Products:
|
|
|
|
Surgical |
|
|
|
General Procedure |
|
|
|
Accessories |
|
|
|
Guidewires
Surgical instruments used to lead other medical devices such as catheters into specific areas of the blood vessels
Buyer Products:
|
|
|
|
Vessel Closure
Devices used to close and repair vascular structures, including both complete systems and associated clamps, felts and pledgets.
Buyer Products:
|
|
|
|
Procedure/Region Specific |
|
|
|
Patency |
|
|
|
Thrombolytic/Embolytic Catheters
Intravascular catheters used to break up plaque build-up and obstructions in blood vessels; thrombus and embolus are composed primarily of platelets/fibrin and platelets/leukocytes combinations respectively.
Buyer Products:
|
|
|
|
Percutaneous Transluminal Angioplasty (PTA) |
|
|
|
Catheters |
|
|
|
Balloon
Catheters equipped with an expanding balloon at the tip
Buyer Products:
|
|
|
|
Embolic Protection Systems
Catheters used to to capture embolic material released during angioplasty and stent
procedures within carotid arteries.
Buyer Products:
|
|
|
|
Guiding
Catheters used to guide the balloon catheter in place.
Buyer Products:
|
|
|
|
Restenosis Prevention |
|
|
|
Stents Systems |
|
|
|
Biliary Tract
Stent inserted into the biliary tract in the liver to prevent future obstruction.
Buyer Products:
|
|
|
|
Iliac Vessels
Stents placed into the iliac arteries to prevent future obstruction; iliac arteries carry the blood from the abdominal aorta to the pelvic region and the lower extremities
Buyer Products:
|
|
|
|
Peripheral
Stents designed to be placed in peripheral blood vessels.
Buyer Products:
|
|
|
|
Renal Arteries
Stent placed in the renal arteries to prevent future obstruction; renal arteries; renal arteries carry the blood from the abdominal aorta to the adrenal glands and excretory organs such as the kidneys and the ureter
Buyer Products:
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements |
|
|
|
Children`s Health
Products consisting of dietary/naturopathic supplements that are intended to support infants and children's health.
Buyer Products:
|
|
|
|
General Health
Products consisting of dietary/naturopathic supplements that are intended to support general health.
Buyer Products:
|
|
|
|
Sports Performance/Energy
Products consisting of dietary/naturopathic supplements that are intended to enhance energy level and athletic performance.
Buyer Products:
|
|
|
|
Weight Management
Products consisting of dietary/naturopathic supplements that are intended to manage obesity, overweight and underweight.
Buyer Products:
|
|
|
|
Outsourced Services |
|
|
|
Drug Delivery Technology |
|
|
|
Oral Delivery |
|
|
|
Polymer Coated
Drug Delivery Technologies used to deliver drugs in a polymer based matrix to hold/enclose the drug.
Buyer Products:
|
|
|
|
Drug Discovery Services |
|
|
|
Lead Discovery/Validation/Optimization |
|
|
|
Lead Biologics |
|
|
|
Antibodies
Biological lead compounds which have a specific amino acid sequence that only interacts with specific substances to cause an immunological response.
Target Products:
|
|
|
|
Scientific Products |
|
|
|
Analytical Instruments |
|
|
|
Automation/Processing Equipment |
|
|
|
Sample Processing Equipment |
|
|
|
Other Processing Equipment
Other sample processing equipment such as extractors and agitators.
Buyer Products:
|
|
|
|
Microscopy |
|
|
|
Consumables
Consumables used for microscopic analysis, such as slides and cover slips.
Buyer Products:
|
|
|
|
Bioanalytical |
|
|
|
Bioanalytical Consumables |
|
|
|
Cell Biology |
|
|
|
Cell Culture |
|
|
|
Media
Cell biology consumables used for the growth of cells or organs.
Buyer Products:
|
|
|
|
Reagents |
|
|
|
Antibiotics
Cell culture reagents that are used during cellular assays.
Buyer Products:
|
|
|
|
Sera |
|
|
|
Animal Sera
Sera obtained from animals.
Buyer Products:
|
|
|
|
Molecular Biology |
|
|
|
Nucleic Acid Analysis |
|
|
|
Kits |
|
|
|
Nucleic Acid |
|
|
|
Hybridization
Nucleic acid analysis kits that are used for the hybridization of genetic samples.
Buyer Products:
|
|
|
|
Labeling
Nucleic acid analysis kits that are used for the labeling of genetic samples, including both nonisotopic and isotopic kits.
Buyer Products:
|
|
|
|
Sequencing
Nucleic acid analysis kits that are used for the sequencing of genetic samples.
Buyer Products:
|
|
|
|
Reagents |
|
|
|
Probes
Nucleic acid analysis reagents labeled with a detectable molecule.
Buyer Products:
|
|
|
|
Biomolecular |
|
|
|
Microarray Technology |
|
|
|
Consumables
Molecular biology consumables used for microarray and biochip instrumentation. Includes kits, chips, and reagents.
Buyer Products:
|
|
|
|
Systems
Microarray/biochip technology components assembled as a single unit.
Buyer Products:
|
|
|
|
Microplate Readers |
|
|
|
Accessories
Supplementary products used to enhance the performance of a microplate reader, including detectors, dispensers, plate handlers, validation plates, and washers. Also includes consumable microplate reader kits.
Buyer Products:
|
|
|
|
Systems |
|
|
|
Single Parameter |
|
|
|
Wavelength
Microplate reader systems that uses wavelength detectors.
Buyer Products:
|
|
|
|
Veterinary Products and Services |
|
|
|
Veterinary Diagnostics
The Veterinary Diganostics Subsector includes companies that manufacture veterinary diagnostics for the detection and monitoring of veterinary diseases.
Buyer Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
GlaxoSmithKline plc (ADR)
|
|
n/a | 93,667.975 | 13.40 | 10.67 | 2.68 | 2.39 | 78.84 | |
|
Genentech, Inc.
|
|
n/a | 81,785.127 | 26.16 | 24.31 | 6.45 | 6.12 | 6.82 | |
|
Medarex inc.
|
|
n/a | 610.859 | n/a | -13.91 | 11.60 | 12.46 | 1.85 | |
| Buyer | |||||||||
|
Roche Holding Ltd. (ADR)
|
|
n/a | 123,605.205 | 14.77 | 14.57 | 3.15 | 2.87 | 5.39 | |
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 93,667.975 | 13.40 | 10.67 | 2.68 | 2.39 | 78.84 | |
|
Genentech, Inc.
|
|
n/a | 81,785.127 | 26.16 | 24.31 | 6.45 | 6.12 | 6.82 | |
|
Sanofi-Aventis SA (ADR)
|
|
n/a | 81,363.100 | 12.87 | 8.19 | 2.24 | 2.10 | n/a | |
|
Amgen, Inc.
|
|
n/a | 61,589.955 | 15.13 | 12.81 | 4.11 | 4.03 | 11.41 | |
|
Siemens AG (ADR)
|
|
n/a | 55,070.769 | 7.58 | 8.08 | 0.56 | 0.50 | 8.10 | |
|
Gilead Sciences, Inc.
|
|
n/a | 41,000.251 | 22.23 | 21.60 | 8.20 | 7.54 | 9.84 | |
|
Bayer AG (ADR)
|
|
n/a | 40,815.858 | 5.65 | 10.31 | 0.89 | 1.00 | n/a | |
|
Medtronic, Inc.
|
|
n/a | 33,446.109 | 15.15 | 10.45 | 2.30 | 2.33 | 11.49 | |
|
Schering-Plough Corporation
|
|
n/a | 27,467.108 | n/a | 9.56 | 1.54 | 1.39 | 14.98 | |
|
Genzyme Corporation
|
|
n/a | 17,640.589 | 42.68 | 18.62 | 3.95 | 3.79 | 4.53 | |
|
Biogen Idec Inc.
|
|
n/a | 13,712.382 | 17.66 | 13.24 | 3.50 | 3.36 | 5.76 | |
|
St. Jude Medical, Inc.
|
|
n/a | 10,786.671 | 15.47 | 13.37 | 2.54 | 2.43 | 8.87 | |
| Target | |||||||||
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 93,667.975 | 13.40 | 10.67 | 2.68 | 2.39 | 78.84 | |
|
Genentech, Inc.
|
|
n/a | 81,785.127 | 26.16 | 24.31 | 6.45 | 6.12 | 6.82 | |
|
Baxter International Inc.
|
|
n/a | 31,107.783 | 16.18 | 15.17 | 2.54 | 2.56 | 5.82 | |
|
Hospira, Inc.
|
|
n/a | 4,280.381 | 14.64 | 11.00 | 1.17 | 1.19 | 17.62 | |
|
Medarex inc.
|
|
n/a | 610.859 | n/a | -13.91 | 11.60 | 12.46 | 1.85 | |
|
Dyax Corp.
|
|
n/a | 207.090 | n/a | -2.65 | 6.87 | 7.62 | n/a | |
|
Sangamo Biosciences, Inc.
|
|
n/a | 133.183 | n/a | -4.41 | 10.99 | 8.82 | 2.47 | |
|
Nuvelo, Inc.
|
|
n/a | 16.099 | n/a | -0.53 | 1.06 | 1.12 | 0.37 | |
|
Boehringer Ingelheim GmbH
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
SurModics, Inc.
|
|
16.00% | 414.963 | 28.15 | 18.02 | 4.28 | 3.50 | 2.93 | |
|
Forward Industries, Inc.
|
|
13.00% | 19.630 | n/a | n/a | 1.00 | n/a | 0.82 | |
|
VirtualScopics, Inc.
|
|
10.90% | 11.732 | n/a | n/a | 1.77 | n/a | 3.26 | |
|
OraSure Technologies, Inc.
|
|
10.00% | 154.610 | n/a | -25.50 | 2.10 | 2.00 | 1.16 | |
|
Hospira, Inc.
|
|
3.90% | 4,280.381 | 14.64 | 11.00 | 1.17 | 1.19 | 17.62 | |
|
Genentech, Inc.
|
|
n/a | 81,785.127 | 26.16 | 24.31 | 6.45 | 6.12 | 6.82 | |
|
Sanofi-Aventis SA (ADR)
|
|
n/a | 81,363.100 | 12.87 | 8.19 | 2.24 | 2.10 | n/a | |
|
AstraZeneca plc (ADR)
|
|
n/a | 56,480.158 | 9.23 | 7.88 | 1.79 | 1.75 | n/a | |
|
FedEx Corporation
|
|
n/a | 19,091.579 | 18.81 | 14.19 | 0.49 | 0.48 | 1.73 | |
|
Biogen Idec Inc.
|
|
n/a | 13,712.382 | 17.66 | 13.24 | 3.50 | 3.36 | 5.76 | |
|
Barr Pharmaceuticals, Inc.
|
|
n/a | 7,146.791 | 49.80 | 22.36 | 2.56 | 2.53 | 16.90 | |
|
Cognizant Technology Solutions Corp.
|
|
n/a | 5,279.227 | 12.73 | 12.41 | 1.98 | 1.86 | 3.22 | |
|
Dassault Systemes S.A. (ADR)
|
|
n/a | 4,865.903 | 18.65 | 15.14 | 2.88 | 2.55 | 2.89 | |
|
Ball Corporation
|
|
n/a | 3,789.268 | 11.88 | 10.55 | 0.50 | 0.48 | n/a | |
|
Elan Corporation, plc (ADR)
|
|
n/a | 3,413.400 | n/a | -12.37 | 3.60 | 3.09 | n/a | |
|
Crown Holdings, Inc.
|
|
n/a | 2,981.332 | 5.27 | 10.69 | 0.36 | 0.34 | n/a | |
|
Techne Corporation
|
|
n/a | 2,396.194 | 21.97 | 21.85 | 8.92 | 8.71 | 5.21 | |
|
Open Text Corporation (USA)
|
|
n/a | 1,407.105 | 23.50 | 11.94 | 1.89 | 1.70 | n/a | |
|
Parametric Technology
|
|
n/a | 1,309.555 | 16.43 | 10.26 | 1.22 | 1.19 | 11.39 | |
|
Crucell N.V. (ADR)
|
|
n/a | 979.587 | n/a | -211.71 | 3.10 | 3.52 | 2.62 | |
|
Martek Biosciences Corp.
|
|
n/a | 912.759 | 20.07 | 21.68 | 2.65 | 2.39 | 1.81 | |
|
Luminex Corporation
|
|
n/a | 873.653 | 72.16 | 331.43 | 8.94 | 9.12 | 6.55 | |
|
Progress Software Corporation
|
|
n/a | 771.750 | 14.86 | 18.77 | 1.50 | 1.46 | 2.84 | |
| Target | |||||||||
|
Seattle Genetics, Inc.
|
|
n/a | 678.890 | n/a | -8.12 | 20.57 | 19.43 | 6.42 | |
|
Highland Distressed Opportunities, Inc
|
|
n/a | 20.374 | n/a | 1.89 | 0.70 | 1.80 | 0.17 | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Genentech, Inc.
|
|
n/a | 81,785.127 | 26.16 | 24.31 | 6.45 | 6.12 | 6.82 | |
|
Bristol Myers Squibb Co.
|
|
n/a | 44,434.739 | 11.35 | 12.69 | 2.14 | 2.03 | 6.45 | |
|
Elan Corporation, plc (ADR)
|
|
n/a | 3,413.400 | n/a | -12.37 | 3.60 | 3.09 | n/a | |
|
Seattle Genetics, Inc.
|
|
n/a | 678.890 | n/a | -8.12 | 20.57 | 19.43 | 6.42 | |
| Buyer | |||||||||
|
Genentech, Inc.
|
|
n/a | 81,785.127 | 26.16 | 24.31 | 6.45 | 6.12 | 6.82 | |
|
Bristol Myers Squibb Co.
|
|
n/a | 44,434.739 | 11.35 | 12.69 | 2.14 | 2.03 | 6.45 | |
|
Gilead Sciences, Inc.
|
|
n/a | 41,000.251 | 22.23 | 21.60 | 8.20 | 7.54 | 9.84 | |
|
Medtronic, Inc.
|
|
n/a | 33,446.109 | 15.15 | 10.45 | 2.30 | 2.33 | 11.49 | |
|
Boston Scientific Corporation
|
|
n/a | 10,765.927 | n/a | 13.96 | 1.31 | 1.35 | n/a | |
|
Cephalon, Inc.
|
|
n/a | 5,133.420 | 20.12 | 15.69 | 2.72 | 2.55 | 14.76 | |
|
Hospira, Inc.
|
|
n/a | 4,280.381 | 14.64 | 11.00 | 1.17 | 1.19 | 17.62 | |
|
Elan Corporation, plc (ADR)
|
|
n/a | 3,413.400 | n/a | -12.37 | 3.60 | 3.09 | n/a | |
|
Gen-Probe Incorporated
|
|
n/a | 2,152.174 | 20.26 | 19.60 | 4.65 | 4.36 | 2.65 | |
| Target | |||||||||
|
Genentech, Inc.
|
|
68.00% | 81,785.127 | 26.16 | 24.31 | 6.45 | 6.12 | 6.82 | |
|
AstraZeneca plc (ADR)
|
|
14.00% | 56,480.158 | 9.23 | 7.88 | 1.79 | 1.75 | n/a | |
|
Roche Holding Ltd. (ADR)
|
|
n/a | 123,605.205 | 14.77 | 14.57 | 3.15 | 2.87 | 5.39 | |
|
Wyeth
|
|
n/a | 47,933.530 | 10.71 | 10.04 | 2.06 | 2.03 | 3.20 | |
|
Bristol Myers Squibb Co.
|
|
n/a | 44,434.739 | 11.35 | 12.69 | 2.14 | 2.03 | 6.45 | |
|
Biogen Idec Inc.
|
|
n/a | 13,712.382 | 17.66 | 13.24 | 3.50 | 3.36 | 5.76 | |
|
Cardinal Health, Inc.
|
|
n/a | 11,701.788 | 9.38 | 8.59 | 0.13 | 0.12 | 7.08 | |
|
McKesson Corporation
|
|
n/a | 9,990.133 | 9.34 | 8.83 | 0.09 | 0.10 | 3.82 | |
|
AmerisourceBergen Corp.
|
|
n/a | 5,164.594 | 20.61 | 10.17 | 0.07 | 0.07 | n/a | |
|
Elan Corporation, plc (ADR)
|
|
n/a | 3,413.400 | n/a | -12.37 | 3.60 | 3.09 | n/a | |
|
Seattle Genetics, Inc.
|
|
n/a | 678.890 | n/a | -8.12 | 20.57 | 19.43 | 6.42 | |
|
Progenics Pharmaceuticals, Inc.
|
|
n/a | 259.793 | n/a | -7.00 | 3.40 | 2.94 | 2.03 | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Roche Holding Ltd. (ADR)
|
|
n/a | 123,605.205 | 14.77 | 14.57 | 3.15 | 2.87 | 5.39 | |
|
Genentech, Inc.
|
|
n/a | 81,785.127 | 26.16 | 24.31 | 6.45 | 6.12 | 6.82 | |
|
Wyeth
|
|
n/a | 47,933.530 | 10.71 | 10.04 | 2.06 | 2.03 | 3.20 | |
|
Bristol Myers Squibb Co.
|
|
n/a | 44,434.739 | 11.35 | 12.69 | 2.14 | 2.03 | 6.45 | |
|
Biogen Idec Inc.
|
|
n/a | 13,712.382 | 17.66 | 13.24 | 3.50 | 3.36 | 5.76 | |
|
Elan Corporation, plc (ADR)
|
|
n/a | 3,413.400 | n/a | -12.37 | 3.60 | 3.09 | n/a | |
|
Seattle Genetics, Inc.
|
|
n/a | 678.890 | n/a | -8.12 | 20.57 | 19.43 | 6.42 | |
| Buyer | |||||||||
|
Roche Holding Ltd. (ADR)
|
|
n/a | 123,605.205 | 14.77 | 14.57 | 3.15 | 2.87 | 5.39 | |
|
Genentech, Inc.
|
|
n/a | 81,785.127 | 26.16 | 24.31 | 6.45 | 6.12 | 6.82 | |
|
Sanofi-Aventis SA (ADR)
|
|
n/a | 81,363.100 | 12.87 | 8.19 | 2.24 | 2.10 | n/a | |
|
AstraZeneca plc (ADR)
|
|
n/a | 56,480.158 | 9.23 | 7.88 | 1.79 | 1.75 | n/a | |
|
Wyeth
|
|
n/a | 47,933.530 | 10.71 | 10.04 | 2.06 | 2.03 | 3.20 | |
|
Bristol Myers Squibb Co.
|
|
n/a | 44,434.739 | 11.35 | 12.69 | 2.14 | 2.03 | 6.45 | |
| Target | |||||||||
|
Roche Holding Ltd. (ADR)
|
|
n/a | 123,605.205 | 14.77 | 14.57 | 3.15 | 2.87 | 5.39 | |
|
Genentech, Inc.
|
|
n/a | 81,785.127 | 26.16 | 24.31 | 6.45 | 6.12 | 6.82 | |
|
Wyeth
|
|
n/a | 47,933.530 | 10.71 | 10.04 | 2.06 | 2.03 | 3.20 | |
|
Bristol Myers Squibb Co.
|
|
n/a | 44,434.739 | 11.35 | 12.69 | 2.14 | 2.03 | 6.45 | |
|
Eli Lilly & Co.
|
|
n/a | 41,396.458 | 17.16 | 8.88 | 2.03 | 1.97 | 3.62 | |
|
Biogen Idec Inc.
|
|
n/a | 13,712.382 | 17.66 | 13.24 | 3.50 | 3.36 | 5.76 | |
|
Cardinal Health, Inc.
|
|
n/a | 11,701.788 | 9.38 | 8.59 | 0.13 | 0.12 | 7.08 | |
|
Elan Corporation, plc (ADR)
|
|
n/a | 3,413.400 | n/a | -12.37 | 3.60 | 3.09 | n/a | |
|
Seattle Genetics, Inc.
|
|
n/a | 678.890 | n/a | -8.12 | 20.57 | 19.43 | 6.42 | |
|
Exelixis, Inc.
|
|
n/a | 522.719 | n/a | -2.38 | 4.45 | 3.34 | n/a | |
|
Progenics Pharmaceuticals, Inc.
|
|
n/a | 259.793 | n/a | -7.00 | 3.40 | 2.94 | 2.03 | |
|
Pierre Fabre Medicament
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 28,798.6 | 296.3 | 29,095.0 |
|
Other Revenue
|
0.0 | 0.0 | 0.0 |
| Total Revenue | 28,798.6 | 296.3 | 29,095.0 |
|
Cost of Revenue
|
12,595.3 | 0.0 | 12,595.3 |
|
SG&A Expense
|
8,017.5 | 77.7 | 8,095.3 |
|
Depreciation & Amortization
|
0.0 | 0.0 | 0.0 |
|
Research & Development
|
2,619.6 | 185.2 | 2,804.7 |
|
Interest Expense
|
0.0 | 0.0 | 0.0 |
|
Other Operating Expense
|
0.0 | -49.7 | -49.7 |
|
Unusual Expense (Income)
|
97.3 | 14.1 | 111.4 |
| Total Expenses | 23,329.7 | 227.3 | 23,557.0 |
|
Operating Income
|
5,468.9 | 69.0 | 5,537.9 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
-143.6 | 1.2 | -142.4 |
|
Other, Net
|
327.6 | 0.0 | 327.6 |
| Income Before Taxes | 5,653.0 | 70.2 | 5,723.2 |
| Income Taxes | 1,105.5 | 4.6 | 1,110.1 |
| Income After Taxes | 4,547.5 | 65.6 | 4,613.1 |
|
Net Income - Excl. Xord. Items
|
4,547.5 | 65.6 | 4,613.1 |
| Discontinued Operations | 0.0 | -53.4 | -53.4 |
|
Net Income - Incl. Xord. Items
|
4,547.5 | 12.2 | 4,559.7 |
|
Income Avail. to Common
|
4,547.5 | 12.2 | 4,559.7 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
1,545.6 | 119.3 | 1,664.9 |
|
Basic EPS - Excl. Xord. Items
|
2.94 | 0.55 | 2.77 |
|
Basic EPS - Incl. Xord. Items
|
2.94 | 0.10 | 2.74 |
| Full Dilution Adjustment | 0.0 | 2.3 | 2.3 |
| Fully Diluted Shares Outstanding | 1,563.7 | 152.8 | 1,716.5 |
|
F.D. EPS - Excl. Xord. Items
|
2.91 | 0.43 | 2.69 |
|
F.D. EPS - Incl. Xord. Items
|
2.91 | 0.08 | 2.66 |
| Dividends Per Common Share | 1.40 | 0.00 | 1.40 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
2,810.3 | 555.3 | 3,365.7 |
|
ST Investments
|
956.1 | 0.0 | 956.1 |
|
Accounts Receivable
|
4,994.1 | 0.0 | 4,994.1 |
|
Inventory
|
3,100.1 | 0.0 | 3,100.1 |
|
Prepayments and Advances
|
3,366.1 | 0.0 | 3,366.1 |
|
Other Current Assets
|
0.0 | 16.4 | 16.4 |
|
Current Assets
|
15,226.7 | 571.7 | 15,798.4 |
|
PPE
|
16,123.4 | 0.0 | 16,123.4 |
|
Accum D&A
|
-8,482.7 | 0.0 | -8,482.7 |
|
PPE, Net
|
7,640.7 | 127.3 | 7,768.0 |
| Goodwill & Intangibles | 16,414.0 | 7.8 | 16,421.8 |
| Long Term Investments | 1,082.0 | 0.0 | 1,082.0 |
| Other Assets | 0.0 | 0.0 | 0.0 |
|
Other LT Assets
|
1,389.6 | 11.5 | 1,401.0 |
| Total Assets | 41,753.0 | 718.2 | 42,471.3 |
| Liabilities | |||
| Accounts Payable | 1,223.8 | 3.5 | 1,227.3 |
| Payable/Accrued | 0.0 | 0.0 | 0.0 |
| Accrued Expenses | 5,689.3 | 52.1 | 5,741.3 |
|
ST Debt
|
595.2 | 0.0 | 595.2 |
|
Curr Port of LTD & Cap Lease Oblg
|
1,501.2 | 0.8 | 1,502.1 |
| Other (Current) Liabilities | 549.9 | 12.2 | 562.0 |
|
Current Liab.
|
9,559.4 | 68.5 | 9,628.0 |
|
LT Debt
|
8,468.0 | 532.9 | 9,001.0 |
|
Total LT Debt
|
8,468.0 | 532.9 | 9,001.0 |
|
Other LT Liab.
|
4,379.7 | 50.4 | 4,430.1 |
|
Total Liabilities
|
22,407.2 | 651.9 | 23,059.0 |
| Shareholders Equity | |||
| Common Stock | 7,309.3 | 1.2 | 7,310.5 |
| Additional Paid in Capital | 0.0 | 629.3 | 629.3 |
| Retained Earnings | 14,276.8 | -563.6 | 13,713.2 |
| Treasure Stock | -2,240.3 | 0.0 | -2,240.3 |
| Other Equity | 0.0 | -0.5 | -0.5 |
|
Total Equity
|
19,345.8 | 66.4 | 19,412.2 |
|
Total Liab. & Equity
|
41,753.0 | 718.2 | 42,471.3 |
|
Shares Outstanding
|
1,551.6 | 119.3 | 1,670.9 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | 4,547.5 | 12.2 | 4,559.7 |
| CF Depreciation | 1,130.6 | 26.2 | 1,156.8 |
| CF Amortization | 768.8 | 7.2 | 776.1 |
| CF Deferred Taxes | 0.0 | -0.3 | -0.3 |
| Other Non-Cash Items | 1,190.7 | 38.0 | 1,228.7 |
| Change in Working Capital | -825.5 | 33.8 | -791.8 |
| Total Cash From Operating Activities | 6,812.1 | 117.1 | 6,929.2 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | -1,451.9 | -15.1 | -1,467.0 |
| Other Investing Cash Flows | -511.8 | 723.1 | 211.3 |
| Total Cash From Investing Activities | -1,963.7 | 708.0 | -1,255.7 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | -2,118.0 | 0.0 | -2,118.0 |
| Purchase Or Sale of Stock | 84.8 | 20.6 | 105.4 |
| Purchase and Retirement of Debt | -1,956.3 | -6.1 | -1,962.4 |
| Other Financing Cash Flow | 0.0 | -494.2 | -494.2 |
| Total Cash From Financing Activities | -3,989.6 | -479.8 | -4,469.3 |
| Exchange Rate Effects | 40.6 | 0.0 | 40.6 |
| Net Change in Cash | 899.5 | 345.3 | 1,244.8 |
| Cash Taxes Paid | 951.6 | 0.2 | 951.8 |
| Cash Interest Paid | 563.9 | 12.4 | 576.3 |